Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program

OBJECTIVE: Tofacitinib is an oral JAK inhibitor indicated for the treatment of rheumatoid arthritis (RA). We characterized lymphoma events in the tofacitinib RA clinical development program. METHODS: Lymphoma events (up to March 2015) were identified from 19 tofacitinib studies (2 phase I, 9 phase I...

Descripción completa

Detalles Bibliográficos
Autores principales: Mariette, Xavier, Chen, Connie, Biswas, Pinaki, Kwok, Kenneth, Boy, Mary G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947561/
https://www.ncbi.nlm.nih.gov/pubmed/28941219
http://dx.doi.org/10.1002/acr.23421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947561/
https://www.ncbi.nlm.nih.gov/pubmed/28941219
http://dx.doi.org/10.1002/acr.23421

Ejemplares similares